Sysmex Corp
TSE:6869
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sysmex Corp
Other Equity
Sysmex Corp
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Sysmex Corp
TSE:6869
|
Other Equity
¥64.1B
|
CAGR 3-Years
64%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
22%
|
|
|
Terumo Corp
TSE:4543
|
Other Equity
¥362.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
Olympus Corp
TSE:7733
|
Other Equity
¥190.8B
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
31%
|
|
|
Nihon Kohden Corp
TSE:6849
|
Other Equity
¥7.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
85%
|
CAGR 10-Years
8%
|
|
|
JEOL Ltd
TSE:6951
|
Other Equity
¥5.3B
|
CAGR 3-Years
51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fukuda Denshi Co Ltd
TSE:6960
|
Other Equity
¥1.7B
|
CAGR 3-Years
299%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
Sysmex Corp
Glance View
In the bustling world of healthcare diagnostics, Sysmex Corporation stands as a beacon of innovation and precision. Originating from the vibrant city of Kobe, Japan, the company has mastered the art of transforming complex scientific processes into streamlined solutions. With roots tracing back to the 1960s, Sysmex emerged as a pioneer in the field of hematology, developing technological marvels that analyze blood components with remarkable accuracy. This precision is not merely an academic pursuit; it translates into actionable insights for medical professionals, empowering them to diagnose and monitor conditions ranging from anemia to leukemia with a high degree of reliability. As the lifeblood of medical laboratories worldwide, Sysmex's automated analyzers and testing systems are indispensable tools in pathologies, enabling swift and accurate patient care. Sysmex's business model is a symphony of product innovation and service excellence. The company thrives by blending advanced technologies with an ever-expanding portfolio of diagnostic instruments and reagents, ensuring that their systems remain both state-of-the-art and user-friendly. Revenue generation for Sysmex is a harmonious balance between instrument sales and the recurring income stream from consumables and after-sales service contracts. This dual approach not only secures initial capital from equipment sales but also ensures sustained engagement with their clients. By investing heavily in research and development, Sysmex continuously pushes the envelope in medical diagnostics, tapping into emerging fields like oncology, hemostasis, and urinalysis. In doing so, it fortifies its position as a global leader, committed to advancing healthcare outcomes through technological innovation and customer-centric practices.
See Also
What is Sysmex Corp's Other Equity?
Other Equity
64.1B
JPY
Based on the financial report for Dec 31, 2025, Sysmex Corp's Other Equity amounts to 64.1B JPY.
What is Sysmex Corp's Other Equity growth rate?
Other Equity CAGR 10Y
22%
Over the last year, the Other Equity growth was 35%. The average annual Other Equity growth rates for Sysmex Corp have been 64% over the past three years , and 22% over the past ten years .